Home / Compare / Tirzepatide vs Retatrutide

Tirzepatide vs Retatrutide

The current GLP-1 leader vs the emerging next-generation triple-agonist. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.

By The Health Stacks Research Team

Tirzepatide

Research

Also: Mounjaro, Zepbound

Tirzepatide is a special medicine that acts like two different hormones in the body at the same time. It is often used by people who need help managing their weight or blood sugar levels.

310 studies687 benefits documented
Where to Source Tirzepatide

Retatrutide

Research

Also: LY3437943

Unapproved and investigational peptides, including popular weight-loss drugs like retatrutide, semaglutide, and tirzepatide, alongside recovery compounds like BPC-157 and TB-500, are entering the U. S.

91 studies450 benefits documented
Where to Source Retatrutide

At a Glance

TirzepatideRetatrutide
Research statusPreclinicalPreclinical
Benefits documented687450
Research citations31091
Dosing routesSubcutaneousSubcutaneous
Known side effects334155

What Each Helps With

Top documented benefits — backed by research.

Tirzepatide

  • Weight loss (~20.9%)
  • Glycemic control
  • Superior to semaglutide 1 mg

Retatrutide

  • Antiobesity (Weight Loss)
  • Weight loss / Obesity treatment
  • Glycaemic control in Type 2 Diabetes
  • Significant weight loss (14.9% reduction over 68 weeks)
  • Significant reduction in liver fat content (up to -82.4% relative change at 24 weeks with 12mg dose)

How People Use It

Reported protocols — research only, not medical advice.

Tirzepatide

  • 15000 mcg, subcutaneous — Chronic weight management / type 2 diabetes
  • subcutaneous — Up to 15 mg
  • subcutaneous — Once weekly
  • subcutaneous — 1.8 mg daily

Retatrutide

  • subcutaneous — 2.4 mg cagrilintide + 2.4 mg semaglutide once weekly
  • subcutaneous — 9 mg weekly
  • subcutaneous — Once weekly
  • subcutaneous — highest dose over 76-week course

The Evidence

Key studies — click through to verify each on PubMed.

Tirzepatide

310 sourced studies

  • Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    RCT2022 Key study 95/100
    Source

  • SURPASS-1: Efficacy and Safety of a Novel Dual GIP/GLP-1 Receptor Agonist

    RCT2021 93/100
    Source

  • Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

    MetaAnalysis2022 88/100
    Source

  • Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

    2025 95/100
    Source

Retatrutide

91 sourced studies

  • Retatrutide’s mechanisms of action

    95/100
    Source

  • The First Triple Agonist for Antiobesity: Retatrutide

    2024 95/100
    Source

  • LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

    2018 95/100
    Source

  • Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

    2023 95/100
    Source

How to Choose

Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.

Full Tirzepatide guide →Full Retatrutide guide →See stacks →

Source Tirzepatide

Find Tirzepatide Suppliers
Tested purity COA available Fast shipping

Source Retatrutide

Find Retatrutide Suppliers
Tested purity COA available Fast shipping
Educational content only. Peptides discussed are generally research compounds, not FDA-approved for human use unless stated. Consult a healthcare professional before use.